Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

IntroductionProgrammed cell death protein 1 (PD-1) and its ligand, PD-L1, are crucial immune checkpoints that regulate the ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

San Francisco, US Tuesday, April 1, 2025, 15:00 Hrs [IST] ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...